Document is current
Any future updates will be listed below
-
Authors
Kummer, Markus P https://orcid.org/0000-0002-0993-2918
Ising, Christina https://orcid.org/0000-0002-7267-3488
Kummer, Christiane
Sarlus, Heela https://orcid.org/0000-0001-7880-9828
Griep, Angelika
Vieira‐Saecker, Ana
Schwartz, Stephanie
Halle, Annett
Brückner, Matthias
Händler, Kristian
Schultze, Joachim L
Beyer, Marc https://orcid.org/0000-0001-9704-148X
Latz, Eicke
Heneka, Michael T https://orcid.org/0000-0003-4996-1630
-
Funding
Funding for this research was provided by:
European Union Seventh Framework Program (INMIND)
Deutsche Forschungsgemeinschaft (KFO177)
Deutsche Forschungsgemeinschaft (IS 299/3‐1)
Deutsche Forschungsgemeinschaft (EXC2151‐390873048)
- License Information
-
More Information
Article History
Received: 6 May 2021
Revised: 27 September 2021
Accepted: 25 October 2021
First Online: 26 November 2021
Conflict of interest
: MTH is a clinical advisory board member at IFM Therapeutics, scientific advisory board member at Alector, and associate editor of Neurology and Neuroinflammation, and received honoraria for oral presentations from Pfizer, Novartis, Roche, AbbVie, and Biogen. All other authors declare that they have no conflict of interest.
